A Novel Method for Dynamically Assessing the Prognosis of Patients with pT1 Gastric Cancer: A Large Population-Based Dynamic Prognostic Analysis

Table 1

Demographic and pathological characteristics of patients selected for further analyses from the SEER database.

Characteristics	Whole cohort		Training cohort		Validation cohort
	N	(%)	n	(%)	n	(%)
Sex
Male	1628	53.98	1064	52.91	564	56.12
Female	1388	46.02	947	47.09	441	43.88
Age
≤40	95	3.15	61	3.03	34	3.38
>40 and ≤50	242	8.02	159	7.91	83	8.26
>50 and ≤60	502	16.64	340	16.91	162	16.12
>60 and ≤70	829	27.49	557	27.70	272	27.06
>70	1348	44.69	894	44.46	454	45.17
Race
White	1514	50.20	1015	50.47	499	49.65
Black	416	13.79	278	13.82	138	13.73
Others	1086	36.01	718	35.70	368	36.62
Tumor location
Upper	112	3.71	71	3.53	41	4.08
Middle	454	15.05	289	14.37	165	16.42
Lower	1355	44.93	905	45.00	450	44.78
Overlapping	1095	36.31	746	37.10	349	34.73
Grade
Well differentiated	371	12.30	249	12.38	122	12.14
Moderately differentiated	956	31.70	644	32.02	312	31.04
Poorly differentiated	1629	54.01	1077	53.56	552	54.93
Undifferentiated	60	1.99	41	2.04	19	1.89
Size
≤1 cm	705	23.38	464	23.07	241	23.98
>1 cm and ≤2 cm	936	31.03	625	31.08	311	30.95
>2 cm and ≤3 cm	606	20.09	400	19.89	206	20.50
>3 cm and ≤4 cm	352	11.67	240	11.93	112	11.14
>4 cm	417	13.83	282	14.02	135	13.43
pT stage
pT1a	1148	38.06	781	38.84	367	36.52
pT1b	1868	61.94	1230	61.16	638	63.48
pN stage
pN0	2397	79.48	1585	78.82	812	80.80
pN1	367	12.17	261	12.98	106	10.55
pN2	180	5.97	120	5.97	60	5.97
pN3a	59	1.96	35	1.74	24	2.39
pN3b	13	0.43	10	0.50	3	0.30
Number of retrieved LNs
≤15	1760	58.36	1178	58.58	582	57.91
>15	1256	41.64	833	41.42	423	42.09
Adjuvant therapy
Yes	499	16.55	333	16.56	166	16.52
No/unknown	2517	83.45	1678	83.44	839	83.48

n, number of patients; LNs, lymph nodes.